This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other cerebrovascular diseases기타 뇌혈관질환

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I67 (Other cerebrovascular diseases) | Special Copayment Reduction: V191 (Special copayment reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsCADASIL, Moyamoya disease, hypertensive encephalopathy, cerebral aneurysm (unruptured), cerebral cortical embolism, cerebral venous thrombosis
C. Adult onsetI67 encompasses various cerebrovascular diseases not included in I60-I66, and the age of onset varies by disease. CADASIL mainly presents in the 30s-50s, and hypertensive encephalopathy in elderly hypertensive patients.
1. HistoryHypertensive encephalopathy began to be described in the late 19th century; the discovery of the CADASIL gene (NOTCH3) in 1994 and research on the pathogenesis of Moyamoya disease in the 2000s are major milestones.
2. CausesVarious causes, including hypertension, genetic mutations (CADASIL), vascular malformations, immune-mediated vasculitis, and metabolic disorders, are involved in I67 subtype diseases.
3. GeneticsNumerous genes, including NOTCH3 (CADASIL), RNF213 (Moyamoya disease), HTRA1 (CARASIL), and COL4A1/COL4A2 (small vessel disease), are associated with I67 subtype diseases.
4. General epidemiologyThe epidemiology of I67 subtype diseases varies: Moyamoya disease is common in East Asian women, CADASIL occurs familially, and hypertensive encephalopathy is common in elderly hypertensive patients.
5. PathophysiologyDepending on the disease, various mechanisms operate, including vascular stenosis-occlusion (Moyamoya), small vessel degeneration (CADASIL), autoregulatory failure due to a sudden rise in blood pressure (hypertensive encephalopathy), and vascular inflammation.
6. SymptomsDepending on the subtype, recurrent stroke (CADASIL, Moyamoya), headache, visual disturbance, and altered consciousness (hypertensive encephalopathy), and progressive cognitive decline (CADASIL) occur.
7. SignsNeurological deficits, papilledema (hypertensive encephalopathy), cognitive decline, vascular bruits, and other findings appear variably depending on the subtype.
8. ScreeningNOTCH3 genetic testing in individuals with a family history of CADASIL, blood pressure monitoring in hypertensive patients, and cerebrovascular MRI/MRA screening in high-risk groups for Moyamoya are recommended.
9. DiagnosisMRI (white matter lesions, infarct patterns), genetic testing (CADASIL), DSA (confirmation of Moyamoya), vessel wall MRI, CSF analysis, and others are used to diagnose the subtype diseases.
10. TreatmentThe main treatments are emergency blood pressure control for hypertensive encephalopathy, cerebral revascularization for Moyamoya disease, and symptomatic treatment and risk factor management for CADASIL.
11. PrognosisIt varies by subtype: hypertensive encephalopathy is reversible with prompt blood pressure control, CADASIL has a poor long-term prognosis with progressive cognitive decline, and Moyamoya is relatively favorable after surgery.
12. PreventionBlood pressure control, smoking cessation, regular cerebrovascular examinations for Moyamoya high-risk groups, and genetic counseling for genetic high-risk groups are the key prevention strategies.
13. ReferencesJoutel A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996 … and 9 other papers

1. History

I67 (other cerebrovascular diseases) in ICD-10 is a broad classification that groups into a single category various cerebrovascular conditions not included in I60-I66, including cerebral aneurysm (unruptured, I67.1), cerebral atherosclerosis (I67.2), progressive vascular leukoencephalopathy (I67.3, including CADASIL), hypertensive encephalopathy (I67.4), Moyamoya disease (I67.5), nonpyogenic thrombosis of the intracranial venous sinuses (I67.6), and cerebral arteritis (I67.7). Each of these has its own unique historical development.

Hypertensive encephalopathy was first described by Oppenheimer and Fishberg in 1914, and the concept was established that when blood pressure rises abruptly, the cerebral autoregulation mechanism breaks down, resulting in cerebral edema and neurological dysfunction. After the clinical spread of MRI in 1987, the imaging findings of posterior reversible encephalopathy syndrome (PRES), characteristic of the occipital white matter, were described, greatly improving the diagnostic accuracy of hypertensive encephalopathy. The history of Moyamoya disease began in 1957 when the Japanese neurosurgeons Takeuchi and Shimizu first reported a case of cerebrovascular occlusion with an abnormal vascular network. In 1969, Suzuki and Takaku reported a basal "puff of smoke" vascular network on cerebral angiography, and the name "Moyamoya disease" became established.

The history of CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) began in 1993 when Tournier-Lasserve et al. first described an autosomal dominant disease causing hereditary small vessel stroke and dementia in a French family. In 1996, Joutel et al. identified NOTCH3 gene variants as the cause, revealing the molecular pathogenesis of CADASIL. Since then, hundreds of pathogenic NOTCH3 variants have been reported worldwide, and it has become established as the representative disease of hereditary small vessel stroke. Cerebral venous sinus thrombosis (CVST) was first described by Ribes in 1825, and in 2004 the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis) systematized its epidemiology and prognosis as a large prospective study.


2. Causes

The causes of the various cerebrovascular diseases included in I67 differ greatly by subcategory. In hypertensive encephalopathy (I67.4), an abrupt rise in blood pressure (malignant hypertension, systolic >220 mmHg or diastolic >120 mmHg) exceeds the cerebrovascular autoregulatory mechanism, causing blood-brain barrier disruption and vasogenic edema. Underlying causes include acute exacerbation of primary hypertension, renovascular hypertension, eclampsia/preeclampsia, pheochromocytoma, cocaine and amphetamine use, and adverse effects of immunosuppressants (cyclosporine, tacrolimus).

The cause of Moyamoya disease (I67.5) has not been fully elucidated, but it is understood that genetic predisposition, including RNF213 gene variants, and environmental factors act in combination to cause progressive stenosis-occlusion of the terminal internal carotid artery and the origins of the middle and anterior cerebral arteries. Moyamoya syndrome arises from various underlying conditions such as Down syndrome, neurofibromatosis type 1 (NF1), sickle cell anemia, cranial radiotherapy, and basal meningitis. CADASIL (I67.3) is caused by variants that alter cysteine residues at specific positions in the EGF-like repeats domain of the NOTCH3 gene; abnormal Notch3 protein accumulates in the smooth muscle cells of small vessels, causing small vessel degeneration and white matter lesions.

Intracranial venous sinus thrombosis (I67.6) has various causes, including pregnancy/puerperium, oral contraceptives, hypercoagulable states (antiphospholipid syndrome, Factor V Leiden, prothrombin G20210A variant, protein C/S deficiency), intracranial infection (bacterial meningitis, otitis media), head trauma, dural arteriovenous fistula, and malignancy. Cerebral arteritis (I67.7) arises from various causes, including primary angiitis of the central nervous system (PACNS), systemic vasculitis (SLE, Behcet disease, polyarteritis nodosa), infectious vasculitis (syphilis, tuberculosis, viral), and drug-induced vasculitis.


3. Genetics

The genetic backgrounds of the diseases in the I67 category are highly diverse. CADASIL is an autosomal dominant inherited disease caused by pathogenic variants of the NOTCH3 gene (chromosome 19). To date, more than 500 pathogenic NOTCH3 variants have been reported, most of which are missense variants involving cysteine residues in the EGF-like repeat domains located in exons 2-24. Abnormal Notch3 protein forms extracellular matrix deposits (GOM, granular osmiophilic material) outside the smooth muscle cells of small vessels, and this material can also be identified by electron microscopy on skin biopsy. The similar disease CARASIL is an autosomal recessive inherited small vessel disease caused by variants of the HTRA1 gene (chromosome 10), reported mainly in East Asians.

The main susceptibility gene for Moyamoya disease is RNF213, and the p.R4810K variant (rs112735431), common in East Asians, is found in about 95% of Japanese familial Moyamoya. RNF213 is presumed to be involved in the regulation of angiogenesis, and having this variant does not necessarily lead to Moyamoya, so its penetrance is known to be low. However, there are also study results showing that the risk of developing Moyamoya in RNF213 p.R4810K carriers is 178 times higher than in non-carriers. COL4A1 and COL4A2 gene variants are associated with hereditary vasculopathies causing cerebral small vessel disease and parenchymal hemorrhage. Important inherited thrombophilic predispositions contributing to intracranial venous sinus thrombosis include variants of the F5 (Factor V Leiden), F2 (prothrombin G20210A), PROC (protein C), PROS1 (protein S), and SERPINC1 (antithrombin III) genes.

A genetic predisposition to posterior reversible encephalopathy syndrome (PRES) has not been established, but associations with blood pressure regulation genes are being explored. The immunogenetic background of primary angiitis of the central nervous system (PACNS) is under study, and polymorphisms of the HLA complex and immune regulatory genes are presumed to be involved.


4. General epidemiology

The subtype diseases of I67 each have different epidemiological characteristics. The frequency of hypertensive encephalopathy increases in populations with a high prevalence of hypertension. The annual incidence of PRES (posterior reversible encephalopathy syndrome) per 100,000 population is not precisely known, but its clinical occurrence is increasing with the rise of immunosuppressive therapy and pregnancy-related hypertension. The annual incidence of Moyamoya disease is about 0.94 per 100,000 population in Japan and 0.56 in Korea, markedly higher than in Western countries. By sex, it is 1.8 times higher in women, and its occurrence shows a bimodal distribution in children (5-10 years) and adults (35-45 years). National registry data from Japan and Korea show a continuously increasing trend in the annual incidence of Moyamoya disease, to which improved diagnosis due to the spread of MRI partly contributes.

The prevalence of CADASIL is estimated at about 4.15 per 100,000 adults, but because diagnosis is difficult and many mild cases are missed, the actual prevalence is presumed to be higher. In Korea as well, tens to hundreds of CADASIL cases are diagnosed each year at medical institutions nationwide, and despite being a rare disease, it is important as the most common single-gene cause of hereditary stroke. The annual incidence of intracranial venous sinus thrombosis (CVST) is about 3-4 per 1,000,000 population, and is much higher during pregnancy and after childbirth and in women taking oral contraceptives. At least one predisposing factor is identified in 75% of adult CVST.

The prevalence of unruptured cerebral aneurysm (I67.1) is about 2-3% of the adult population, and it is often discovered incidentally. It is about 2 times higher in women than in men, and higher in smokers, hypertensive patients, and those with a family history. The annual risk of rupture (SAH) is 0.1-2% depending on aneurysm size, location, and shape. With the spread of cerebral angiography, the number of asymptomatic incidental aneurysms detected continues to increase.


5. Pathophysiology

The pathophysiology of the I67 subtype diseases differs for each, but they share the common theme of cerebrovascular dysfunction. For the mechanism of hypertensive encephalopathy (PRES), the theory of cerebral autoregulation failure is the most widely supported. Normally, cerebral vessels have an autoregulatory capacity that keeps cerebral blood flow constant within a mean arterial pressure range of 50-150 mmHg. When blood pressure exceeds this range, vessels dilate passively, cerebral blood flow increases sharply, and the blood-brain barrier is disrupted, resulting in vasogenic edema. Lesions concentrate in the parieto-occipital lobes because sympathetic innervation of this region is sparse, making regulation of vasoconstriction-vasodilation vulnerable.

In the pathophysiology of Moyamoya disease, vessel wall degeneration such as intimal thickening, smooth muscle cell proliferation, and fragmentation of the elastic lamina progresses in the terminal internal carotid artery and the proximal cerebral arteries, leading to progressive stenosis and occlusion. In compensation, an abundant basal collateral vascular network (Moyamoya vessels) develops, but these vessels are structurally fragile and at risk of rupture. Ischemic symptoms (especially in children) arise from insufficient collateral circulation, and hemorrhagic complications (more common in adults) result from rupture of the fragile Moyamoya vessels. In CADASIL, abnormal Notch3 protein accumulates outside the smooth muscle cells of small vessels, causing abnormalities in vascular maturation and function. Notch3 protein accumulation leads to abnormal PDGF-β signaling, altered vasoconstrictive responses, and impaired blood-brain barrier function, inducing recurrent small infarcts and progressive white matter lesions.

In intracranial venous sinus thrombosis, thrombus formation in the venous sinuses impairs intracranial venous drainage, resulting in cerebral venous hypertension. This causes venous infarction (hemorrhagic transformation is common), cerebral edema, and increased intracranial pressure. Thrombi form when blood stasis (procoagulant effect of female hormones, dehydration, pregnancy), vessel wall injury (head trauma, meningitis), and a hypercoagulable state (inherited thrombophilia) combine, as explained by Virchow's triad.


6. Symptoms

The clinical symptoms of the I67 subtype diseases vary greatly with the condition. The characteristic symptoms of hypertensive encephalopathy/PRES are headache (severe and throbbing), seizures, altered consciousness, and visual disturbance (including cortical blindness). Symptoms develop over hours to days after an abrupt rise in blood pressure, and the key feature is reversible improvement with prompt blood pressure control. PRES caused by immunosuppressants (cyclosporine, tacrolimus) occurs even at relatively low blood pressure, and concomitant renal failure worsens the prognosis.

Symptoms of Moyamoya disease differ by age. In children, recurrent TIAs or minor strokes triggered by hyperventilation (intracranial vasoconstriction occurring when blowing up balloons), headache, and delayed cognitive development are characteristic. In adults, intracranial hemorrhage (rupture of Moyamoya vessels) is more common, with sudden headache, nausea and vomiting, and decreased consciousness. The characteristic symptoms of CADASIL are recurrent ischemic attacks in the 30s-50s, headache (migraine-like, especially migraine with aura), psychiatric symptoms (depression, apathy), and gradually progressive cognitive decline. Neurological deficits accumulate even after attacks, eventually progressing to dementia and motor impairment.

In intracranial venous sinus thrombosis, headache is the most common symptom (90%), with a progressive or thunderclap pattern. Seizures (40%), focal neurological deficits (43%), and decreased consciousness may accompany it. Visual disturbance and diplopia can occur from abducens nerve palsy due to increased intracranial pressure. CVST is sometimes diagnosed in patients visiting migraine or headache clinics, so attention is needed for headache of a new pattern or suddenly worsened headache.


7. Signs

Physical examination findings observed in the I67 subtype diseases also vary. In hypertensive encephalopathy/PRES, blood pressure is measured at very high values (>200/120 mmHg), and fundoscopy shows findings of hypertensive retinopathy such as papilledema, retinal hemorrhage, and cotton-wool spots. Neurological examination may reveal altered consciousness (coma, delirium), a postictal state, and visual loss due to cortical blindness. In Moyamoya disease, focal neurological deficits (hemiparesis, speech disturbance, visual abnormalities) repeatedly appear transiently and then recover, or, when hemorrhagic complications occur, rapid decline in consciousness and neurological deterioration appear.

In patients with CADASIL, cumulative neurological deficits from multiple small infarcts lead to progressive signs of pseudobulbar palsy such as gait disturbance, dysphagia, dysarthria, and "stomach twisting". Cognitive decline centers on frontal executive dysfunction (impaired planning and abstraction, attention deficits) and clinically progresses to vascular dementia. In intracranial venous sinus thrombosis, nausea and vomiting, abducens nerve palsy (diplopia), and papilledema appear as signs of increased intracranial pressure, and focal neurological deficits due to venous infarction are also observed.

The characteristic finding of Moyamoya disease on cerebral angiography is stenosis-occlusion of the terminal internal carotid artery and development of smoke-like collateral vessels around the basal ganglia. The MRI findings of CADASIL are characterized by T2 hyperintense changes in the bilateral frontotemporal white matter, the external capsule, and the anterior temporal lobe, accompanied by multiple small infarcts and interhemispheric white matter abnormalities. Anterior temporal white matter abnormality is a nearly pathognomonic MRI finding of CADASIL and is important for differentiation.


8. Screening

Screening strategies differ by I67 subtype. When there is a family history of CADASIL (especially family members who experienced stroke, recurrent TIA, or early dementia in their 30s-50s), NOTCH3 gene variant testing is recommended. Before genetic testing, if MRI shows anterior temporal white matter abnormalities, external capsule lesions, or a basal ganglia small infarct pattern, CADASIL is highly likely and genetic testing follows. Diagnosis is also possible by confirming GOM deposition with electron microscopy on skin biopsy, but genetic testing is more commonly used. In high-risk groups for Moyamoya disease (family members of RNF213 variant carriers, those with underlying diseases of Moyamoya syndrome), regular surveillance with brain MRI and MRA is recommended.

In high-risk groups for unruptured cerebral aneurysm (I67.1) (two or more first-degree relatives with a history of cerebral aneurysm or SAH, ADPKD, Marfan syndrome, prior history of SAH), regular screening with MRA or CTA is recommended (after age 10-20, at 5-year intervals). The high-risk periods for intracranial venous sinus thrombosis (CVST) are pregnancy and the puerperium and while taking oral contraceptives; if new headache or visual disturbance develops during these periods, immediate evaluation with MRI/MRV (MR venography) is recommended. In those with a thrombotic predisposition (inherited thrombophilia, antiphospholipid syndrome), appropriate prophylactic anticoagulation around high-risk situations (pregnancy, after surgery) is important for CVST prevention.

Screening for prevention of hypertensive encephalopathy requires assessing blood pressure control in hypertensive patients with regular blood pressure monitoring and 24-hour ambulatory blood pressure monitoring (ABPM), and education about prodromal symptoms of hypertensive crisis. Stricter blood pressure monitoring is recommended especially in patients with secondary hypertension due to renal disease or pheochromocytoma.


9. Diagnosis

Diagnosis of the I67 subtype diseases requires specific tests for each. Hypertensive encephalopathy/PRES is diagnosed when clinical symptoms (headache, seizures, altered consciousness, visual abnormalities) are accompanied by bilateral T2/FLAIR hyperintense changes (vasogenic edema) centered on the parieto-occipital lobes on MRI. On DWI, absence of diffusion restriction suggests reversible vasogenic edema (PRES), while presence of diffusion restriction suggests irreversible infarction. Reversible improvement of imaging findings after prompt blood pressure control supports the diagnostic criteria for PRES.

Moyamoya disease is confirmed by directly visualizing stenosis-occlusion of the terminal internal carotid artery and basal collateral vessels with DSA (digital subtraction angiography). MRA and CTA are used as screening tests, but because resolution of collateral vessels may be low, especially in children, DSA is used for confirmation. On brain MRI, DWI infarct patterns ("thickness-type" cortical infarcts, deep small infarcts), white matter abnormalities on FLAIR, and the "ivy sign" (leptomeningeal vessel dilation) on SWI are characteristic. The standard for diagnosing CADASIL is NOTCH3 genetic testing (identification of a clinical variant), and confirmation of GOM by skin biopsy is also possible. On MRI, anterior temporal white matter abnormalities and a pattern of external capsule and basal ganglia small infarcts strongly suggest CADASIL.

Intracranial venous sinus thrombosis is diagnosed with a combination of MRI and MRV or CT and CTV. Thrombus within a venous sinus is identified as high signal on T1 (subacute thrombus), low signal on gradient echo, and a sinus filling defect on venography. Elevated serum D-dimer suggests CVST, but a negative result cannot exclude it. To identify the cause, thrombophilia genetic testing, antiphospholipid antibodies, hormone tests, and infection cultures are needed. MRA is mainly used for screening and follow-up of cerebral aneurysm (I67.1), and when size is ≥7mm or the shape is irregular, detailed evaluation is performed with CTA or DSA.


10. Treatment

The key to treating hypertensive encephalopathy/PRES is removal of the cause and prompt blood pressure control. Mean arterial pressure is lowered by 20-25% within the first hour, and then gradually adjusted to a target systolic blood pressure of 160 mmHg or less. Excessively rapid lowering of blood pressure can cause ischemic injury by reducing cerebral perfusion. Preferred intravenous agents are labetalol and nicardipine, and nitroprusside is avoided because of the risk of increased intracranial pressure. Seizures are controlled with antiseizure medications (lacosamide, valproic acid, levetiracetam), and in PRES caused by immunosuppressants, dose reduction or substitution of the drug is necessary.

Medical treatment of Moyamoya disease consists of antiplatelet agents (aspirin) and symptom management, but the definitive treatment is cerebral revascularization. Direct bypass (STA-MCA anastomosis) and indirect bypass (EDAS, EDAMS) are mainly used, and direct bypass is more effective for immediate blood supply. In both children and adults, surgery is effective in preventing recurrence of ischemia and hemorrhage. CADASIL currently has no definitive treatment; antiplatelet agents for stroke prevention, blood pressure and glucose control, trials of acetylcholinesterase inhibitors (donepezil) to slow cognitive decline, and migraine prophylaxis are given symptomatically. Warfarin is not recommended in CADASIL because it may increase the risk of intracranial hemorrhage.

Anticoagulation is the key to treating intracranial venous sinus thrombosis, and continuing anticoagulation is recommended even in the presence of hemorrhagic transformation. Acute treatment begins with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH), followed by a switch to a DOAC (dabigatran, rivaroxaban, apixaban) or warfarin. The duration of long-term anticoagulation is determined by the cause and the risk of recurrence (at least 3-6 months; long-term maintenance in cases of recurrence or inherited thrombophilia). When intracranial pressure is markedly elevated, acetazolamide, ventricular drainage, or decompressive craniectomy may be necessary.


11. Prognosis

The prognosis of the I67 subtype diseases differs greatly by disease. In hypertensive encephalopathy/PRES, if detected promptly and blood pressure is controlled, imaging findings and clinical symptoms mostly improve reversibly within days to weeks. However, if treatment is delayed or irreversible infarction occurs, permanent neurological deficits may remain. The risk of recurrence is high when the underlying cause (hypertension, renal disease, immunosuppressants) persists. In Moyamoya disease, the recurrence rate of ischemic stroke decreases markedly after surgical revascularization, and the postoperative neurodevelopmental course is favorable, especially in children. However, in adult Moyamoya with hemorrhagic presentation, the risk of rebleeding does not disappear completely even after surgery.

CADASIL is a progressive disease in which dementia develops on average within about 10 years after diagnosis, often progressing thereafter to a bedridden state and death. Life expectancy varies greatly among individuals depending on the NOTCH3 variant type, occurrence of stroke, blood pressure management, and other factors. Active management of risk factors (hypertension, smoking) may significantly affect the rate of disease progression. The prognosis of intracranial venous sinus thrombosis is better than previously thought, with neurological recovery achieved in 80-90% under appropriate anticoagulation. Mortality is about 8-10%, and malignant intracranial hypertension is the most important cause of death. The risk of recurrence is highest in the first 3-12 months, and long-term anticoagulation is needed in patients with inherited thrombophilia or antiphospholipid syndrome because of their high recurrence rate.

In the natural history of unruptured cerebral aneurysm, aneurysms <7mm in size have a low annual rupture risk of 0.1-1%, but the rupture risk increases with size ≥7mm, anterior or posterior communicating artery location, irregular shape, and a history of prior SAH. Based on the 5-year rupture risk estimated with the PHASES score, an individualized decision is made between preventive treatment (coil embolization or clip ligation) and observation.


12. Prevention

Prevention strategies also differ for each I67 subtype. The most important measures for prevention of hypertensive encephalopathy are active treatment of hypertension and education in home blood pressure measurement. Systolic blood pressure is kept below 130 mmHg, and blood pressure control is checked through regular visits to a medical institution. Causes of secondary hypertension such as renal disease, pheochromocytoma, and eclampsia are detected and treated early. In pregnant women, blood pressure monitoring is intensified, and low-dose aspirin prophylaxis is considered when risk factors for preeclampsia (nulliparity, multiple pregnancy, obesity) are present.

There is currently no known method for prevention of Moyamoya disease, but early detection through regular cerebrovascular imaging in high-risk families (families of RNF213 variant carriers) is important. In patients with underlying diseases of Moyamoya syndrome (NF1, Down syndrome, etc.), changes in symptoms should be observed carefully, and if an abnormality is suspected, they should be evaluated immediately by a neurologist. In patients who have received cranial radiotherapy, regular cerebrovascular imaging follow-up is recommended considering the possibility of Moyamoya syndrome due to radiation vasculopathy.

For prevention of CADASIL, to delay symptom onset, avoidance of smoking (smoking accelerates progression of white matter lesions), treatment of hypertension, and diabetes control are important, with smoking cessation especially emphasized. In gene variant carriers, it is recommended to avoid triptans, which are the cause of severe migraine attacks. When familial CADASIL is confirmed, genetic counseling supports genetic testing and early diagnosis and treatment of family members, and preconception genetic counseling helps them understand the genetic risk and make decisions.


13. References

  1. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6602):707-710. DOI: 10.1038/383707a0. PMID: 8878478.

  2. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299. DOI: 10.1001/archneur.1969.00480090076012. PMID: 5775283.

  3. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. DOI: 10.1056/NEJM199602223340803. PMID: 8559202.

  4. Ferro JM, Canhão P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-670. DOI: 10.1161/01.STR.0000117571.76197.2C. PMID: 14976332.

  5. Kim JS, Oh CW, Kwon OK, et al. Postoperative outcomes of moyamoya disease: a nationwide prospective registry in Korea. Stroke. 2020;51(2):429-436. DOI: 10.1161/STROKEAHA.119.026618. PMID: 31813376.

  6. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8(7):643-653. DOI: 10.1016/S1474-4422(09)70127-9. PMID: 19539236.

  7. Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78(11):803-810. DOI: 10.1212/WNL.0b013e318249f71f. PMID: 22402864.

  8. Ferro JM, Aguiar de Sousa D. Cerebral venous thrombosis: an update. Curr Neurol Neurosci Rep. 2019;19(10):74. DOI: 10.1007/s11910-019-0988-x. PMID: 31399823.

  9. Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103-110. DOI: 10.1016/S0140-6736(03)13860-3. PMID: 12867109.

  10. Kim BJ, Lee SH. Prognostic impact of cerebral small vessel disease on stroke outcome. J Stroke. 2015;17(2):101-110. DOI: 10.5853/jos.2015.17.2.101. PMID: 26060798.